- Home
- RPRX vs NIO Comparison
RPRX vs NIO Comparison
Compare RPRX & NIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- NIO
- Stock Information
- Founded
- RPRX 1996
- NIO 2014
- Country
- RPRX United States
- NIO China
- Employees
- RPRX N/A
- NIO N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- NIO Auto Manufacturing
- Sector
- RPRX Health Care
- NIO Consumer Discretionary
- Exchange
- RPRX Nasdaq
- NIO Nasdaq
- Market Cap
- RPRX 11.7B
- NIO 12.1B
- IPO Year
- RPRX 2020
- NIO 2018
- Fundamental
- Price
- RPRX $26.29
- NIO $4.32
- Analyst Decision
- RPRX Strong Buy
- NIO Buy
- Analyst Count
- RPRX 6
- NIO 12
- Target Price
- RPRX $41.67
- NIO $7.04
- AVG Volume (30 Days)
- RPRX 3.3M
- NIO 57.3M
- Earning Date
- RPRX 11-06-2024
- NIO 11-20-2024
- Dividend Yield
- RPRX 3.19%
- NIO N/A
- EPS Growth
- RPRX 518.56
- NIO N/A
- EPS
- RPRX 2.55
- NIO N/A
- Revenue
- RPRX $2,266,003,000.00
- NIO $9,000,115,178.00
- Revenue This Year
- RPRX $12.21
- NIO $29.95
- Revenue Next Year
- RPRX $11.13
- NIO $45.50
- P/E Ratio
- RPRX $10.29
- NIO N/A
- Revenue Growth
- RPRX N/A
- NIO 15.67
- 52 Week Low
- RPRX $25.10
- NIO $3.61
- 52 Week High
- RPRX $31.66
- NIO $9.57
- Technical
- Relative Strength Index (RSI)
- RPRX 43.34
- NIO 38.01
- Support Level
- RPRX $25.47
- NIO $4.31
- Resistance Level
- RPRX $26.83
- NIO $4.92
- Average True Range (ATR)
- RPRX 0.53
- NIO 0.25
- MACD
- RPRX 0.08
- NIO -0.00
- Stochastic Oscillator
- RPRX 61.66
- NIO 12.49
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About NIO NIO Inc. American depositary shares each representing one ordinary share
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold over 160,000 EVs in 2023, accounting for about 2% of the China passenger new energy vehicle market.